The usefulness of dopaminergic drugs in traumatic brain injury;Utilidad de los fármacos dopaminérgicos en el daño cerebral de origen traumático

Revista de Neurologia

Volumn 35, Issue 4, 2002, Pages 362-366

  Orient Lopez F ^a   Terre Boliart, R ^a   Bernabeu Guitart, M ^a   Ramon Rona S ^a   Perez Miras A ^a  

^a University Institute affiliated with the Autonomous University of Barcelona   (Spain)

Author keywords

Amantidine; Bromocriptine; Dopaminergic agents; Head injury; Neuropsychological deficit; Rehabilitation; Treatment

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CARBIDOPA; DOPAMINE RECEPTOR AFFECTING AGENT; ENTACAPONE; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TOLCAPONE;

BRAIN INJURY; COGNITIVE DEFECT; DISABILITY; HEAD INJURY; HUMAN; MEDLINE; MOTOR DYSFUNCTION; REVIEW;

EID: 0037119562     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3504.2001457     Document Type: Review

References (36)

1. White RJ, Likavec MJ. The diagnosis and initial management of head injury. N Engl J Med 1992; 327: 1507-11.
2. Karli DC, Burke DT, Kim HJ, Calvanio R, Fitzpatricks M, Temple D, et al. Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation. Brain Inj 1999; 13: 63-8.
3. Nickels JL, Schneider WN, Dombovy ML, Wong TM. Clinical use of amantadine in brain injury rehabilitation. Brain Inj 1994; 8: 709-18.
4. Kraus MF, Maki P. The combined use of amantadine and L-dopa/carbidopa in the treatment of chronic brain injury. Brain Inj 1997; 11: 455-60.
5. Muñoz-Céspedes JM, Paúl-Lapedriza N, Pelegrín-Valero C, Tirapu-Ustarroz J. Factores de pronóstico en los traumatismos craneoencefálicos. Rev Neurol 2001; 32: 351-64.
6. Suárez JI. Manejo del traumatismo craneal cerrado. Rev Neurol 2001; 32: 289-95.
7. León-Carrión J. Traumatismos craneales en España. Anuario 1998. Noticias Médicas 1998; 3686: 32-4.
8. Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: Case studies and review. J Neuropsychiatry Clin Neurosci 1997; 9: 222-30.
9. Marin RS, Fogel BS, Hawkins J, Duffy J, Krupp B. Apathy: A treatable syndrome. J Neuropsychiatry Clin Neurosci 1995; 7: 23-30.
10. Terre R, Pérez A, Roig T, Bernabeu M, Ramón S. Tratamiento farmacológico con amantadina en pacientes con lesión cerebral. Rehabilitación 2002. (In press).
11. Zafonte RD, Watanabe T, Mann NR. Amantadine: A potential treatment for the minimally conscious state. Brain Inj 1998; 12: 617-21.
12. Bascufiana H, Villarreal I, Alfonso S, Terre R, Bernabeu M. Agitación en el traumatismo craneoencefálico. II. Tratamiento con antidepresivos, simpaticomiméticos, betabloqueantes, dopaminérgicos y otros fármacos. Rev Neurol 2000; 30: 1044-7.
13. Shiller AD, Burke DT, Kim HJ, Calvanio R, Dechman KG, Santini C. Treatment with amantadine potentiated motor learning in a patient with traumatic brain injury of 15 years duration. Brain Inj 1999; 13: 715-21.
14. Mysiw WJ, Sandel ME. The agitated brain injured patient. Part 2: Pathophysiology and treatment. Arch Phys Med Rehabil 1997; 78: 213-20.
15. Fugate LP, Spacek LA, Kresty LA, Levy CE, Johnson JC, Mysiw WJ. Measurement and treatment of agitation following traumatic brain injury. II. A survey of the brain injury special interest group of the American Academy of Physical Medicine and Rehabilitation. Arch Phys Med Rehabil 1997; 78: 924-8.
16. Zafonte RD, Lexell J, Cullen N. Possible applications for dopaminergic agents following traumatic brain injury. Part 1. J Head Trauma Rehabil 2000; 15: 1179-82.
17. Zafonte RD, Lexell J, Cullen N. Possible applications for dopaminergic agents following traumatic brain injury. Part 2. J Head Trauma Rehabil 2000; 16: 112-6.
18. Cope DN. Psychopharmacologic aspects of traumatic brain injury. In Horn LJ, Zesler R, eds. Medical rehabilitation of traumatic brain injury. Philadelphia: Hanley and Belfus; 1996. p. 573-612.
19. O'Dell MW, Riggs RV. Management of the minimally responsive patient. In Horn LJ, Zesler R, eds. Medical Rehabilitation of Traumatic Brain Injury. Philadelphia: Hanley and Belfus; 1996. p. 103-32.
20. Müller U, von Cramon Y. The therapeutic potential of bromocriptine in neuropsychological rehabilitation of patients with acquired brain damage. Prog Neuropsycopharmacol Biol Psychiatry 1994; 18: 1103-20.
21. Powell JH, al-Adawi S, Morgan J, Greenwood RJ. Motivational deficits after brain injury: Effects of bromocriptine in 11 patients. J Neurol Neurosurg Psychiatry 1996; 60: 416-21.
22. Sitland-Marken PA, Wells BG, Froemming JH. Psychiatric applications of bromocriptine therapy. J Clin Psychiatry 1990; 51: 68-82.
23. Dobkin B, Hanlon R. Dopamine agonist treatment of antegrade amnesia from a mediobasal forebrain injury. Ann Neurol 1993; 33: 313-6.
24. McDowell S, Whyte J, D'Esposito M. Differential effect of dopaminergic agonist on prefrontal function in traumatic brain injury patients. Brain 1998; 121: 1155-64.
25. Kornhuber J, Söller M, Schoppmeyer K, Riederer P. Amantadine and memantadina are NMDA receptor antagonist with neuroprotective properties. J Neural Transm Suppl 1994; 43: 91-104.
26. Van Reekum R, Bayley M, Garner S, Burke IM, Fawcett S, Hart A, et al. N of I study: Amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj 1995; 9: 49-53.
27. Wilkinson R, Meythaler JM, Guin-Renfroe S. Case study. Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. Brain Inj 1999; 13: 1025-31.
28. Schneider W, Drew-Cates J, Wong T, Dombrovy M. Cognitive and behavioral efficacy of amantadine in acute traumatic brain injury: An initial double-blind placebo controlled study. Brain Inj 1999; 13: 863-72.
29. 2-receptor agonist. Br J Clin Pharmacol 1989; 28: 435-41.
30. Adler CH, Sethi KD, Hauser RA. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997; 49: 393-9.
31. Kuzel M. Ropinirole: A dopamine agonist for the treatment of Parkinson's disease. Am J Health Syst Pharm 1999; 56: 217-24.
32. Becker P, Ondo W, Sharon D. Encouraging initial response of restless legs syndrome to pramipexole. Neurology 1998; 51: 1221-3.
33. Maj J, Rogoz Z, Skuza G, Kolodziejczyk K. Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm 1997; 104: 525-33.
34. Jungerman T, Rabinowitz D, Klein E. Deprenyl augmentation for treating negative symptoms of schizophrenia: A double blind, controlled study. J Clin Psychopharmacol 1999; 19: 522-5.
35. Rajput AH, Martin W, Saint Hilaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the 'wearing-off' phenomenon: A double blind, placebo-controlled, multicenter trial. Neurology 1997; 49: 1066-71.
36. Rinne UK, Larsen JP, Siden A, Worm-Peterson J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998; 51: 1309-14.